pre-IPO PHARMA

Sensei Biotherapeutics Announces Formation of New Immuno-Oncology Advisory Board

Tags:   Oncology   Immuno-Oncology   Advisory Board  

- Company brings together world-recognized leaders in immunobiology, cancer biology, and clinical and translational medicine -


GAITHERSBURG, Md.--(BUSINESS WIRE)--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, today announced the formation of a new Immuno-Oncology Advisory Board (IOAB), consisting of several world-recognized and credentialed experts in the fields of immuno-oncology, tumor biology, vaccinology, cell therapy, and precision medicine. The IOAB will collaborate closely with members of Sensei’s management team to support the advancement of the Company’s pipeline of ASPH-targeted precision immuno-oncology therapies and bring complementary expertise to guide the future of the company.


“We are honored to have such a highly distinguished team of experts in the field of immune-oncology join our newly formed advisory board,” said John Celebi, Chief Executive Officer of Sensei. “Each of these appointees is globally recognized for their work. We look forward to working closely with them as we continue to develop our suite of novel therapies against next generation targets, including ASPH, and work to profoundly impact the health and quality of life for patients with unmet needs.”



The members of the Sensei’s IOAB include:

About Sensei Biotherapeutics

Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies to transform the cancer treatment landscape. The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine, and SNS-723, its cell therapy program in preclinical development for solid tumors and hematological cancers. These programs target ASPH, a novel embryonic antigen. Sensei’s precision medicine approach in immuno-oncology includes the use of companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit www.senseibio.com.


Contacts

Media:Kathryn MorrisThe Yates Network914-204-6412kathryn@theyatesnetwork.com


Investor:Julie SeidelStern Investor Relations, Inc.212-362-1200julie.seidel@sternir.com


Media:Kathryn MorrisThe Yates Network914-204-6412kathryn@theyatesnetwork.com


Investor:Julie SeidelStern Investor Relations, Inc.212-362-1200julie.seidel@sternir.com